Telmicard 40 mg Tab. - 40mg

Tablet

Pack Size : 14 Tablet x 1 Strip

Generics : Telmisartan + Amlodipine

Manufacturer : Drug International Ltd.

Best Price * TK 112.00

* Delivery will be done in Dhaka city only.

Alternative Product

Tablet Arbitel - 20mg ACI Limited

Tk 7.00

Tablet Cardotel Plus - 5 mg Pharmasia Ltd.

Tk 14.00

Tablet Telmacal - 40mg Beximco Pharmaceuticals Ltd.

Tk 12.50

Tablet Telmacal 5/80 mg Tab. - 80mg Beximco Pharmaceuticals Ltd.

Tk 20.00

Tablet Telmipres 80 - 80mg Incepta Pharmaceuticals Ltd.

Tk 11.00

More Information About - Telmicard 40 mg Tab. - 40mg

Description

Generic Name

Telmisartan

Precaution

Avoid fetal or neonatal exposure, Hypotension, Monitor carefully in patients with impaired hepatic or renal function, Avoid concomitant use of an ACE inhibitor and angiotensin receptor blocker. Hepatic insufficiency, biliary obstruction, renal impairment, renaly artery stenosis. Correct volume depletion before initiating treatment. Monitor serum potassium levels regularly, especially in elderly and renally-impaired patients.

Indication

Hypertension in adults, Reduction of cardiovascular morbidity in adults with atherothrombotic cardiovascular disease, (history of coronary heart disease, stroke, or peripheral arterial disease), Type 2 diabetes mellitus, with documented target organ damage.

Contra Indication

Severe hepatic impairment, biliary obstructive disorders. Pregnancy. Lactation.

Dose

N/A

Side Effect

1-10% Upper respiratory tract infection (URTI) (7%),Back pain (3%),Diarrhea (3%),Myalgia (3%),Sinusitis (3%),Chest pain (1%),Hypertension (1%),Headache (1%),Dizziness (1%),Pharyngitis (1%) <1% Abnormal ECG,Anemia,Angina,Angioedema,Bradycardia,Eczema,Epistaxis,Gout,Hypercholesterolemia,Hyperkalemia,Hypoglycemia,Otitis media Potentially Fatal: Rarely angioedema, rash, pruritus and urticaria.

Pregnancy Category

Name : D

Description

There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

Mode of Action

Telmisartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptor in many tissues, such as vascular smooth muscle and the adrenal gland. Its action is therefore independent of the pathways for angiotensin II synthesis.

Interaction

May increase plasma levels of digoxin. May increase serum lithium levels and toxicity. May reduce plasma levels of warfarin. Increased risk of hyperkalaemia w/ K-sparing diuretics, K supplements or K-containing salt substitutes. May antagonise hypotensive effect and increase risk of renal impairment w/ NSAIDs. Potentially Fatal: May increase nephrotoxic, hyperkalaemic and hypotensive effect w/ aliskiren in patients w/ diabetes and renal impairment (GFR <60 mL/min).

Pregnancy Category Note

Pregnancy category: 1st trimester, C; 2nd and 3rd trimesters, D Lactation: Not known whether drug is excreted in breast milk; avoid using

Adult Dose

Oral Hypertension Adult: Dosage must be individualized. The usual starting dose of Telmisartan tablets is 40 mg once a day. Blood pressure response is dose-related over the range of 20 to 80 mg. Most of the anti hypertensive effect is apparent within 2 weeks and maximal reduction is generally attained after 4 weeks. When additional blood pressure reduction beyond that achieved with 80 mg Telmisartans is required, may switch to combination, a diuretic may be added. Telmisartan tablets may be administered with other antihypertensive agents. Initial therapy with Telmisartan is not recommended in patients >75 years old or with hepatic impairment Elderly: No initial dosage adjustment is necessary for elderly patients. Cardiovascular risk reduction Adult:The recommended dose of telmisartan tablets is 80 mg once a day. It is not known whether doses lower than 80 mg of telmisartan are effective in reducing the risk of cardiovascular morbidity and mortality. When initiating telmisartan therapy for cardiovascular risk reduction, monitoring of blood pressure is recommended, and if appropriate, adjustment of medications that lower blood pressure may be necessary. Hepatic impairment: Initial therapy with telmisartan is not recommended in patients ?75 years old or with hepatic impairment.

Child Dose

<18 years old: Safety and efficacy not established

Renal Dose

Renal impairment: No initial dosage adjustment is required for patients with mild to moderate renal impairment. Titrate slowly in patients with severe renal impairment. Patients on dialysis may develop orthostatic hypotension; their blood pressure should be closely monitored.

Administration

May be taken with or without food.

Disclaimer

The information provided herein are for informational purposes only and not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please note that this information should not be treated as a replacement for physical medical consultation or advice. Great effort has been placed to provide accurate and comprehensive data. However, Medicart along with its authors and editors make no representations or warranties and specifically disclaim all liability for any medical information provided on the site. The absence of any information and/or warning to any drug shall not be considered and assumed as an implied assurance of the Company.